Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (Abstract P3.04-085).
Vassiliki Papadimitrakopoulou, MD, of MD Anderson Cancer Center, discusses the ways in which patients, investigators, and pharmaceutical companies are working together to accelerate research and access to care (Abstract MTE 02.01).
James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice early lung cancer detection in the target population of tobacco-exposed individuals (Abstract MS 15.01).
Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.
Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of sensitivity to afatinib or neratinib (Abstracts ORAL 3.01, 3.02, and 3.03).
Everett E. Vokes, MD, of the University of Chicago, summarizes expert views on treating stage IIIA disease: decision-making in selecting patients for surgery; multiple-modality choices; and using induction chemotherapy (Abstract ED10).
